Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients
Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)
DOI: 10.1128/aac.01950-24 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Rujia Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Ltd, Singapore, Singapore. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc., Innovative Medicines Initiative, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated pneumonia, and other infections due to aerobic gram-negative organisms with limited treatment options. Pharmacokinetic data from two phase 3 trials were added to previous data to develop a simultaneous aztreonam and avibactam population pharmacokinetic model. The final model was used to simulate exposures by infection type and renal function and estimate the joint probability of pharmacodynamic target attainment (PTA) for phase 3 patients (aztreonam 60% f T >MIC ATM-AVI of 8 mg/L and avibactam 50% f T >C T of 2.5 mg/L). Additional simulations evaluated simplified loading doses, regimens for end-stage renal disease, and ceftazidime-avibactam + aztreonam regimens. The final model included 4,914 aztreonam plasma samples (431 subjects) and 18,222 avibactam plasma samples (2,635 subjects). A two-compartment model with zero-order infusion and first-order elimination best fit the data. Time-varying creatinine clearance was a key covariate on clearance for both drugs, whereas infection type was a key covariate on clearance and volume, with the lowest exposures observed in patients with cIAI. Final aztreonam-avibactam dose regimens achieved joint PTA 89% to >99% at steady state across renal function groups. Ceftazidime-avibactam + aztreonam dose regimens proposed by the Infectious Diseases Society of America (IDSA) achieved joint PTA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Ltd, Singapore, Singapore.
- Pfizer Inc, New York, New York, USA.
- Pfizer Inc, Collegeville, Pennsylvania, USA.
- Pfizer Inc, Sandwich, Kent, United Kingdom.
- Pfizer Inc, La Jolla, California, USA.
ORCID-Profile: Joseph W Chow, Elena Soto, Susan R Raber
Förderung
- Pfizer Inc.
- Innovative Medicines Initiative
- Biomedical Advanced Research and Development Authority
Zitieren
APA
Xie, R., Rogers, H., Chow, J. W., Soto, E., & Raber, S. R. (2025). Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.01950-24
Vancouver
Xie R, Rogers H, Chow JW, Soto E, Raber SR. Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.01950-24
BibTeX
@article{Xie2025,
author = {Xie, Rujia and Rogers, Halley and Chow, Joseph W and Soto, Elena and Raber, Susan R},
title = {Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {8},
doi = {10.1128/aac.01950-24}
}
EUVIMED